Trials / Unknown
UnknownNCT01758367
Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Decitabine can up-regulate a series of immune associated proteins, including cancer testis antigens (CTA), major histocompatibility complex (MHC), co-stimulatory molecules and adhesion molecules, which suggests a potential benefit for a following adoptive T cell therapy. In addition, decitabine induce FOXP3 expression in CD4+ T cells and convert CD4+ T cells into T regulatory cells(Tregs). As a result, Graft versus host disease(GVHD) can be reduced by treatment of decitabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deciatbine(DAC) |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2017-06-01
- Completion
- 2018-06-01
- First posted
- 2013-01-01
- Last updated
- 2016-08-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01758367. Inclusion in this directory is not an endorsement.